Literature DB >> 10220488

Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole.

M A Gibbs1, K L Kunze, W N Howald, K E Thummel.   

Abstract

The purpose of this work was to evaluate the effect of mutual unbound inhibitor and unbound enzyme depletion on the potency of three antifungal cytochrome P-450 (CYP)3A inhibitors with over 1000-fold range in enzyme affinity. Incubations were performed with human liver microsomal protein concentrations that varied from 25 to 1000 microg/ml. The effect of each inhibitor was evaluated using midazolam as a CYP3A probe. Clotrimazole was found to be a tight binding inhibitor of CYP3A with a Ki of 250 pM. Analysis of percent inhibition data by stepwise linear regression for the matrix of inhibitor and enzyme concentrations used showed that protein concentrations predicted the percent inhibition by clotrimazole (r2 = 0.60, p <.001). When clotrimazole concentrations were added to the model, the r2 improved to 0.81, p =.003. Clotrimazole concentrations alone were not a significant predictor of percent inhibition (r2 = 0. 21, p =.08). For ketoconazole, protein concentrations provided a weak prediction of the percent inhibition (r2 = 0.39, p =.006). Conversely, ketoconazole concentrations alone were a good predictor of percent inhibition (r2 = 0.55, p <.001). In contrast to results with clotrimazole and ketoconazole, percent inhibition by fluconazole was not dependent on protein concentrations (r2 = 0.06, p =.39). We conclude that microsomal inhibitory potency can be affected by incubation conditions that deplete the unbound concentration of inhibitor available to the enzyme. This may introduce serious error into a quantitative prediction of an in vivo drug-drug interaction based on an in vitro derived Ki value.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10220488

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  11 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene.

Authors:  D Ouellet; C Bramson; D Roman; A E Remmers; E Randinitis; A Milton; M Gardner
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

3.  Effects of oral clotrimazole troches on the pharmacokinetics of oral and intravenous midazolam.

Authors:  Stacy S Shord; Lingtak-Neander Chan; Joseph R Camp; Eva M Vasquez; Hyun-Young Jeong; Robert E Molokie; Charles L Baum; Hui Xie
Journal:  Br J Clin Pharmacol       Date:  2010-02       Impact factor: 4.335

4.  Effect of CYP3A5 genotype, steroids, and azoles on tacrolimus in a pediatric renal transplant population.

Authors:  Shwetal Lalan; Susan Abdel-Rahman; Andrea Gaedigk; J Steven Leeder; Bradley A Warady; Hongying Dai; Douglas Blowey
Journal:  Pediatr Nephrol       Date:  2014-05-30       Impact factor: 3.714

5.  Impact of the CYP3A5*1 Allele on the Pharmacokinetics of Tacrolimus in Japanese Heart Transplant Patients.

Authors:  Takaya Uno; Kyoichi Wada; Sachi Matsuda; Yuka Terada; Akira Oita; Atsushi Kawase; Mitsutaka Takada
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-12       Impact factor: 2.441

Review 6.  Factors affecting the clinical development of cytochrome p450 3A substrates.

Authors:  Megan A Gibbs; Natilie A Hosea
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Phosphorylation increases the catalytic activity of rainbow trout gill cytosolic carbonic anhydrase.

Authors:  Daniel Carrie; Kathleen M Gilmour
Journal:  J Comp Physiol B       Date:  2016-01       Impact factor: 2.200

8.  Evaluation of a Novel Renewable Hepatic Cell Model for Prediction of Clinical CYP3A4 Induction Using a Correlation-Based Relative Induction Score Approach.

Authors:  Rongjun Zuo; Feng Li; Sweta Parikh; Li Cao; Kirsten L Cooper; Yulong Hong; Jin Liu; Ronald A Faris; Daochuan Li; Hongbing Wang
Journal:  Drug Metab Dispos       Date:  2017-01-06       Impact factor: 3.922

9.  A π-Halogen Bond of Dibenzofuranones with the Gatekeeper Phe113 in Human Protein Kinase CK2 Leads to Potent Tight Binding Inhibitors.

Authors:  Alexander Schnitzler; Andreas Gratz; Andre Bollacke; Michael Weyrich; Uwe Kuckländer; Bernhard Wünsch; Claudia Götz; Karsten Niefind; Joachim Jose
Journal:  Pharmaceuticals (Basel)       Date:  2018-02-17

10.  Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant.

Authors:  H Wulff; M J Miller; W Hansel; S Grissmer; M D Cahalan; K G Chandy
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.